Journals / Turkish Journal of Rheumatology(.)Archives of Rheumatology / 2011 / Cilt: 26 - Sayı: 3

Türk Çocuklarında Juvenil Dermatomiyozit

Juvenile Dermatomyositis in Turkish Children

Pages
233–238
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although juvenile dermatomyositis is a rare disease in childhood, it may have severe complications

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to determine the clinical features of juvenile dermatomyositis (JDM) in Turkish children.
📊
Key Findings & Data:Patients and methods: The clinical records of nine children with JDM who were followed up in the Department of Pediatric Nephrology and Rheumatology of Erciyes University Faculty of Medicine between January 1992 and December 2008 were reviewed retrospectively.
💡
Conclusion & Impact:Conclusion: Although juvenile dermatomyositis is a rare disease in childhood, it may have severe complications
🔬Design:Review & Systematic Survey
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to determine the clinical features of juvenile dermatomyositis (JDM) in Turkish children. Patients and methods: The clinical records of nine children with JDM who were followed up in the Department of Pediatric Nephrology and Rheumatology of Erciyes University Faculty of Medicine between January 1992 and December 2008 were reviewed retrospectively. Results: The female to male ratio was 2:1. The median age at onset of the disease was 8.8 years (range 6.5-14 years), the median duration of symptoms before diagnosis was two months (range 10 days-72 months), and the mean time of follow-up was 49.5 months (range 2-96 months). The main presenting complaints were arthritis/arthralgia, myalgia, an impaired ability to walk, and skin rashes. Eight patients received oral steroids as the initial therapy. Additionally, two patients received intravenous methylprednisolone, and five received non-steroidal anti- inflammatory drugs during the follow-up. Three patients received methotrexate, and one received cyclosporine A. The median time to treatment response was 60 days (range 10-70 days). Pathological proteinuria was found in two patients. Subcutaneous calcinosis developed in one patient. Skin and soft-tissue infections occurred in two patients. Other complications seen during the follow-up were malnutrition, obesity, depressive mood, ototoxicity, muscle weakness, osteoporosis, and contractures. Conclusion: Although juvenile dermatomyositis is a rare disease in childhood, it may have severe complications

Özet

Amaç: Bu çalışma Türk çocuklarda juvenil dermatomiyozitin (JDM) klinik özelliklerini tanımlamayı amaçlamaktadır.Hastalar ve yöntemler: Ocak 1992 - Aralık 2008 tarihleri arasında Erciyes Üniversitesi Tıp Fakültesi Çocuk Nefroloji ve Romatoloji Departmanı'nda takip edilmiş olan dokuz JDM'li çocuğun tıbbi kayıtları retrospektif olarak incelendi.Bulgular: Kız erkek oranı 2:1 idi. Hastalığın başlangıç yaş ortancası 8.8 yıl (dağılım 6.5-14 yıl), tanı öncesi semptomların ortanca süresi iki ay (dağılım 10 gün-72 ay), ortalama takip süresi ise 49.5 ay (dağılım 2-96 ay) idi. Başlıca başvuru yakınmaları artrit/artralji, miyalji, yürüme yeteneğinde bozukluk ve ciltte döküntü idi. Başlangıç tedavisi olarak sekiz hastaya oral steroid verildi. Takipleri sırasında ek olarak, iki hastaya intravenöz metilprednizolon, beş hastaya nonsteroid antiinflamatuvar ilaçlar verildi. Üç hastaya metotreksat ve bir hastaya siklosporin A verildi. Tedaviye yanıt gelişene kadar geçen ortanca süre 60 gün (dağılım 10-70 gün) idi. İki hastada patolojik proteinüri tespit edildi. Bir hastada cilt altında kalsinozis oluştu. İki hastada cilt ve yumuşak doku infeksiyonu gelişti. Beslenme bozukluğu, şişmanlık, depresif duygu durumu, ototoksisite, kas güçsüzlüğü, osteoporoz ve kontraktürler hastaların takipleri sırasında görülen diğer komplikasyonlardı.Sonuç: Juvenil dermatomiyozit çocukluk çağında nadir görülen bir hastalık olmasına rağmen ciddi komplikasyonları olabilir

🔖

Cite This Article

TÜLPAR, S., GÜNDÜZ, Z., DÜŞÜNSEL, R., BAŞTUĞ, F. (2011). Türk Çocuklarında Juvenil Dermatomiyozit. Turkish Journal of Rheumatology(.)Archives of Rheumatology, Cilt: 26 - Sayı: 3, 233–238. https://ajindex.com/articles/376011

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Woo P, Laxer RM, Sherry DD. Juvenile dermatomyositis. In: Woo P, Laxer RM, Sherry DD, editors. Pediatric Rheumatology in clinical practice. 1st ed. London: Springer; 2007. p. 66-76.
  2. Compeyrot-Lacassagne S, Feldman BM. Inflammatory myopathies in children. Pediatr Clin North Am 2005;52:493-520.
  3. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12.
  4. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
  5. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009;60:1825-30.
  6. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
  7. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)-clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006;45:1255-60.
  8. Pachman LM, Hayford JR, Hochberg MC. Seasonal onset in juvenile dermatomyositis: an epidemiological study. Arthritis Rheum 1992;35:S88. Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997;23:619-55.
  9. Dourmishev LA, Dourmishev AL. Pharmacologic agents in the treatment of DM. In: Dourmishev LA, Dourmishev AL, editors. Dermatomyositis advances in recognition, understanding and management. 1st ed. Berlin: Springer; 2009. p. 297-322. Winfield J. Juvenile dermatomyositis with complications. Proc R Soc Med 1977;70:548-51.
  10. Cohen BH, Sedwick LA, Burde RM. Retinopathy of dermatomyositis. J Clin Neuroophthalmol 1985;5:177-9.
  11. Lenoble P, Desprez P, Fischbach M, Flament J, Sahel J. Ocular involvement in dermatomyositis. Apropos of the case of a 15-year-old girl. J Fr Ophtalmol 1995;18:312-6. [Abstract] Akikusa JD, Tennankore DK, Levin AV, Feldman BM. Eye findings in patients with juvenile dermatomyositis. J Rheumatol 2005;32:1986-91.
  12. Yeo LM, Swaby DS, Situnayake RD, Murray PI. Irreversible visual loss in dermatomyositis. Br J Rheumatol 1995;34:1179-81.
  13. Soylu A, Kavukçu S, Türkmen M, Saroğlu S. Dermatomyositis with membranous ne